Microdosing Compounded GLP-1 / GIP
For Him & Her
Weight loss

Microdosing Compounded GLP-1 / GIP

Some individuals find that appetite regulation and metabolic function are influenced by more than one pathway. In these cases, a single approach may not feel sufficient or consistent over time. Microdosing GLP-1 / GIP uses a dual-hormone approach with smaller, more frequent dosing designed to support steadier appetite signaling and a more gradual adjustment process. At Kingdom, providers tailor dosing strategies based on your response, tolerance, and overall health profile to determine whether this approach may be appropriate.
$
129

/mo
4-month plan
Start your journey
Compounded GLP-1 / GIP and GLP-1  medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not equivalent to FDA-approved products. Kingdom partners with licensed U.S. pharmacies that compound medications pursuant to valid prescriptions and applicable laws.
Who is it for?

A more tailored approach to appetite and metabolic support.

If you have tried other approaches and they have not felt consistent, or you prefer a more gradual and controlled dosing strategy, this may be worth discussing. Some individuals explore this option when they want support across multiple metabolic pathways while maintaining a routine that feels manageable day-to-day. At Kingdom, treatment plans are built around your response, tolerance, and long-term goals.
Fit man and woman in athletic wear standing confidently against a brown background with text 'Your peak performance, secured.'
Benefits
The pillars of your transformation
Support appetite regulation across pathways
Targets hormone signals involved in hunger and satiety.
A more gradual approach to dosing
Smaller, more frequent dosing may feel easier to tolerate.
Support day-to-day consistency
Designed to fit into routines without abrupt changes.
Built around your response
Dosing is adjusted based on how your body responds over time.
The Science

How dual-hormone signaling supports appetite regulation.

GLP-1 and GIP are hormones involved in appetite control, digestion, and glucose regulation. They help signal hunger, fullness, and how the body processes energy. Microdosing approaches use smaller, more frequent administrations to support more consistent signaling across these pathways. This may help reduce abrupt changes in appetite and improve tolerability for some individuals. At Kingdom, dosing strategies are based on clinical response, health profile, and provider evaluation.
The Clinical Journey

Guided by experts

Your treatment is not built from a template. Kingdom providers use lab work, health history, and ongoing check-ins to shape a protocol tailored to how your body responds over time.

Get Started
01
02
03

Take our quiz

Answer a few quick questions to help us understand your goals and medical history.

Meet your provider

Person having a video consultation with a doctor on a laptop showing a smiling male doctor in a white coat.

Meet with a specialized clinician who reviews your data and designs a strategy tailored to you.

Begin your journey

Receive your custom protocol at your doorstep with continuous clinical oversight to ensure your long-term success.

Explore More

Health is a Kingdom

Your optimization might go further. Discover how our other protocols can complement your wellness journey.
Hormone
Therapy
Vial of kingdom Testosterone Cypionate with red and white capsules labeled kingdom floating around it.
Wellness
Glass vial labeled Kingdom NAD+ with green cap, next to green tablets embossed with the letter K.
FAQS

For every question, an expert answer.

If your question isn't here, don't worry, Ask our experts for clarity on your journey. We’re here to help.

How does microdosing affect tolerability?

Lower per-dose exposure can reduce abrupt shifts in appetite and digestion, which may help some individuals adjust more gradually over time.

‍

Who is typically considered for GLP-1/GIP microdosing?

Often discussed in individuals who want a more gradual dosing strategy or who have not responded consistently to single-pathway approaches.

‍

What is the benefit of targeting both GLP-1 and GIP?

GLP-1 primarily influences satiety and gastric emptying, while GIP plays a role in insulin signaling and nutrient handling, allowing multiple metabolic pathways to be engaged together.

‍

Why might a dual-pathway approach feel different from GLP-1 alone?

Engaging both incretin pathways can change how appetite, energy use, and glucose response are regulated, rather than relying on a single signaling mechanism.

‍

How does GLP-1/GIP microdosing work?

It uses smaller, more frequent doses to maintain steadier activation of both GLP-1 and GIP receptors, rather than creating larger peaks from standard dosing schedules.

‍